Q3 2020 Sales Performance

belantamab mafodotin 2L pivotal studies initiated (DREAMM-7 and DREAMM-8) Development strategy for use in: 4L/3L monotherapy and combinations gsk Study start Est launch relapsed/ DREAMM-1 pilot refractory patients Belantamab mafodotin monotherapy, single arm, n=73 2014 DREAMM-2 pivotal daratumumab failures Belantamab mafodotin monotherapy, single arm, n=223 Jun 2018 2020 Approved DREAMM-3 pivotal failed lenalidomide and proteasome inhibitor Belantamab mafodotin monotherapy vs. PomDex, n=320 1H 2020 2023 relapsed/ Belantamab mafodotin + PD1 combination, DREAMM-4 pilot Mar 2019 refractory patients single arm, n=40 DREAMM-5 pilot relapsed/ Belantamab mafodotin + novel Oct 2019 refractory patients combinations platform study, n=514 Belantamab mafodotin+LenDex OR DREAMM-6 pilot failed 1 prior therapy Oct 2018 +BorDex, open label, n= 99 2L 209418 ISS relapsed/ refractory patients Belantamab mafodotin+PomDex, n= 78 Jan 2019 combination with SOC DREAMM-7 pivotal failed 1 prior therapy Belantamab mafodotin+BorDex vs.. Dara+BorDex, n= 478 1H 2020 2024 DREAMM-8 pivotal failed 1 prior therapy '916+PomDex vs. PomBorDex, n= 450 2H 2020 2023 1L combination with novel and SOC agents DREAMM-9 pilot transplant ineligible Belantamab mafodotin+BorLen Dex vs. n=70 Jan 2020 DREAMM-10 pivotal transplant ineligible Belantamab mafodotin+novel agent vs SOC, n=TBC 2022 52 52

View entire presentation